Interestingly, the treatment of mouse syngeneic tumor models with EZH2 inhibitors resulted in the accumulation of CD11b+Gr1+ cells in the tumor tissue, an increase in M1 macrophages with the consequent decrease in M2 macrophages, as well as a reduction in IFN-γ-producing CD8+ and CD4+ T-cells [198] (Figure 4C). The gene discussed is EZH2; the disease is neoplasm.